Inflammation · 2016 · 55 citations · 51 references
MedicineCardiologyPharmacologyClinical PharmacologyInflammationMolecular PharmacologyAnti-inflammatory PharmacologyCardiac MedicationsCardiac PharmacotherapyCardiovascular DiseaseCytokine BiologyDiabetes PharmacotherapyChemokine BiologyChemokine ModulationDiabetic CardiomyopathyImmune-mediated CardiomyopathyInflammation In Cardiovascular DiseasePhosphodiesterase InhibitionPhosphodiesterase Type 5 Inhibitor TherapyPhosphodiesterase Type 5 Inhibitors
T helper 1 (Th1) type cytokines and chemokines are bioactive mediators in inflammation underling several diseases and co-morbid conditions, such as cardiovascular and metabolic disorders. Th1 chemokine CXCL10 participates in heart damage initiation/progression; cardioprotection has been recently associated with sildenafil, a type 5 phosphodiesterase inhibitor. We aimed to evaluate the effect of sildenafil on CXCL10 in inflammatory conditions associated with diabetic cardiomyopathy. We analyzed: CXCL10 gene and protein in human cardiac, endothelial, and immune cells challenged by pro-inflammatory stimuli with and without sildenafil; serum CXCL10 in diabetic subjects at cardiomyopathy onset, before and after 3 months of treatment with sildenafil vs. placebo. Sildenafil significantly decreased CXCL10 protein secretion (IC50 = 2.6 × 10(-7)) and gene expression in human cardiomyocytes and significantly decreased circulating CXCL10 in subjects with chemokine basal level ≥ 930 pg/ml, the cut-off value as assessed by ROC analysis. In conclusion, sildenafil could be a pharmacologic tool to control CXCL10-associated inflammation in diabetic cardiomyopathy.
51
IL-10 inhibits cytokine production by activated macrophages
David Fiorentino, Albert Zlotnik, Tim R. Mosmann et al. · The Journal of Immunology · 1991 · 2.9K citations · Full text
Louis J. Ignarro, Margaret A. Bush, Georgette M. Buga et al. · Biochemical and Biophysical Research Communications · 1990 · 849 citations